Recent Updates
Recently added Catalysts

CP- 690, 550 and Tacrolimus

Phase 1

Healthy Volunteers | Small molecule | Other |Pfizer, Inc.|Last Updated: Aug 13, 2009

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment24

FDA Designations

No designations recorded

Clinical trial landscape

CP- 690, 550 and Tacrolimus · 1 trial · 1 indication

Phase 1 1
NCT00860496A Phase I Open-Label Study of the Effects of Tacrolimus and Cyclosporine on CP-690,555 in Healthy VolunteersHealthy Volunteers
COMPLETED24 Analytics
PHASE1COMPLETED
A Phase I Open-Label Study of the Effects of Tacrolimus and Cyclosporine on CP-690,555 in Healthy Volunteers
Healthy Volunteers
NCT0086049624
Unlock trial analytics

Study Endpoints

Primary Endpoints

Effect of multiple dose Tacrolimus and Cyclosporine on the pharmacokinetics of a single oral dose of CP-590,550 in healthy volunteers
9 days

Secondary Endpoints

Evaluate the safety and tolerability of a single oral dose of CP-690,550 when co-administered with Tacrolimus or Cyclosporine
9 days
Unlock Study Endpoints

Study Design & Arms

MaskingNONE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
1OTHERTreatment Arm 1 will receive one single dose of CP-690,550 on Day 1, Tacrolimus on Days 1-8, and one single dose of CP-690,550 on Day 8.
2OTHERTreatment Arm 2 will receive one single dose of CP-690,550 on Day 1, Cyclosporine on Days 1-6, and one single dose of CP-690,550 on Day 6.

Interventions

NameTypeDescription
CP- 690,550 and TacrolimusDRUG10 mg, single dose of CP-690,550 on Day 1 5 mg, every 12 hours of Tacrolimus on Days 1-8 10 mg, single dose of CP-690,550 on Day 8
CP- 690,550 and CyclosporineDRUG10 mg, single dose of CP-690,550 on Day 1 200 mg, every 12 hours of Cyclosporine on Days 1-6 10 mg, single dose of CP-690,550 on Day 6
Unlock Study Design Details

Eligibility Criteria

Age Range21 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy males between 21 and 55 years, inclusive. * Healthy females of non-childbearing potential between 21 and 55 years, inclusive. * Total body weight greater than 132 pounds. Exclusion Criteria: * Evidence or history of clinically significant disease * Females of childbe...

Countries:Singapore
Unlock Eligibility Criteria

Frequently asked questions about CP- 690, 550 and Tacrolimus

What is CP 690,550 used for?

CP 690,550 is an investigational small molecule being studied for multiple conditions, including renal impairment, Crohn's disease, hepatic insufficiency, dry eye syndromes, rheumatoid arthritis, and psoriasis. It is developed by Pfizer, Inc. (NYSE: PFE) and is currently in Phase 3 clinical development.

What does CP 690,550 target?

CP 690,550 is a small molecule immunology therapeutic. Its specific molecular target is not disclosed in the available information. It is being investigated for its potential role in treating autoimmune and inflammatory conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease.

Who makes CP 690,550?

CP 690,550 is developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 3 clinical trials for various indications, including psoriasis and rheumatoid arthritis.

What phase is CP 690,550 in?

CP 690,550 is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Pfizer, Inc. is conducting clinical trials to evaluate its safety and efficacy for conditions such as psoriasis and other inflammatory diseases.

What clinical trials is CP 690,550 in?

CP 690,550 has been studied in several clinical trials, including NCT00678210, a Phase 2 study in moderate to severe chronic plaque psoriasis, and NCT01519089, a Phase 3 long-term study in patients with moderate to severe plaque psoriasis and/or psoriatic arthritis. All trials are completed.

Is CP 690,550 the same as tofacitinib?

CP 690,550 is an alternative name for tofacitinib, a small molecule developed by Pfizer, Inc. It is being studied for various indications, including rheumatoid arthritis, psoriasis, and Crohn's disease. The drug is currently in Phase 3 clinical development.